TPM3 and cancer: The low incidence in the current dataset is likely because these cancers are not yet routinely tested for the presence of NTRK fusions but rather are diagnosed clinicopathologically and/or immunophenotypically, or that patients often present with early-stage disease and are therefore not eligible for treatment with TRK inhibitors [32].